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Regarding “A novel molecular mechanism to account
for the action of simvastatin against limb ischemia”
In the article by Koksoy and colleagues,1 the authors describe
that simvastatin markedly suppresses the functional activity of
neutrophils, which is underscored by reduced myeloperoxidase
activity compared with a placebo. I would like to add to the
discussion of Koksoy and coworkers1 by introducing a major route
through which simvastatin could suppress the activity of neutro-
phils.
The recent focus on ischemia-reperfusion injury has been
on interaction between neutrophils and endothelial cells. The
injury attributed to plugging of the microvasculature by neu-
trophils may initiate the cascade of injury by releasing free
radicals, enzymes, and cytokines, and physically injuring the
endothelium and obstructing the capillaries, thus, impairing
oxygen supply to the tissue. Also, transendothelial migration of
neutrophils, with release of reactive oxygen species and cyto-
kines, causes further damage to the injured tissue.2,3 However,
a key component in the pathogenesis of reperfusion syndrome is
the upregulation of surface adhesion molecules on the vascular
endothelium and their subsequent interaction with the acti-
vated neutrophils.4 The most important adhesion protein iden-
tified on neutrophils is the integrin lymphocyte function-asso-
ciated antigen-1 (LFA-1; CD11a/CD18), which is the ligand
for intercellular adhesion molecule-1 (ICAM-1) expressed on
the endothelium. The LFA-1/ICAM-1 interaction is crucial for
the ingress of neutrophils into the inflammatory sites.5,6 Simva-
statin downregulates the expression of ICAM-1 and LFA-1, and
through binding to LFA-1, it interferes with ICAM-1–LFA-1
interaction.7,8 This important mechanism should be borne in
mind as the major mechanism for simvastatin-induced inhibi-
tion of neutrophil activity.
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Reply
Dr Namazi’s comments offer additional insight to our study.
Ischemia reperfusion injury provokes complex pathophysiologic
network involving distinct cell populations and humoral media-
tors. As pointed by the Dr Namazi, the most crucial step is
activation of the interaction between neutrophils and endothelial
cells. In our study, our primary purpose was to clarify the effects of
simvastatin pretreatment on the limb ischemia reperfusion injury in
an experimental diabetes model. Several techniques were used to
assess tissue injury including tissue myeloperoxidase (MPO) enzy-
matic activity as a measure of neutrophil infiltration. Statin pre-
treatment reduced the MPO activity compared with the untreated
groups. Unfortunately, we did not attempt to further define the
mechanisms for simvastatin induced inhibition of neutrophil activ-
ity. We agree with Dr Namazi who suggested that a key compo-
nent in the pathogenesis of reperfusion injury is upregulated
interaction between neutrophils and endothelial cells especially
LFA-1/ICAM-1 pathway.1,2 It has been shown that statins ame-
liorate tissue injury by concomitantly reducing expression of
LFA-1 and/or ICAM-1 in several ischemia reperfusion models
including the retina,3 brain, 4 and the bowel.5 Neutrophil adhesion
to the endothelium indicates a major component of ischemia/
reperfusion pathophysiology and may be a target for therapeutic
intervention.
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Regarding “Vascular abnormalities in patients with
neurofibromatosis syndrome type I: Clinical
spectrum, management, and results”
We read the article by Oderich et al1 and would like to add one
more case that we recently had who underwent a successful oper-
ation.
The patient is a 38-year old woman with neurofibromatosis
type I who has a history of bilateral renal and abdominal aortic
angioplasty, at the age of 10 and 2 years ago, for severe hyperten-
sion measuring 240/120.
The patient presented for vascular consultation on November
6, 2006, with recurrent hypertension and ischemic symptoms of
the lower extremities. Preoperative evaluation revealed suprarenal
stricture extending to the juxtarenal and infrarenal aorta with
bilateral renal artery stenoses. Rheumatology evaluation was essen-
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tially negative. On March 30, 2007, the patient underwent a
successful surgical repair, including descending thoracic aorta–left
renal artery (side-to-side anastomosis), and sequential right renal
artery (end-to-side anastomosis) using one limb of a No. 16
Hemashield (Boston Scientific, Natick, Mass) double-velour Da-
cron Y-graft. The other limb of the graft was extended down to the
left common iliac artery for end-to-side anastomosis (Fig 1).
During the surgery, the patient had multiple fibromatoses
in the intestine, measuring 2 mm and 20 mm in size. The patient
also had a neurofibromatosis lesion in the oral cavity, involving
the supraglottis, and a retropharyngeal region, without signifi-
cant respiratory problem or difficulty with swallowing.
Since reconstructive surgery, the patient has become normo-
tensive and completely asymptomatic from the lower extremity
ischemic symptoms. The patient had exertional dyspnea, which
was also completely dissipated.
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The authors are to be congratulated on their success with a case
of neurofibromatosis vasculopathy presenting with renovascular hy-
pertension, aortic and renal artery stenosis. Neurofibromatosis is
among the most common inherited human diseases. The cardinal
features of café au lait macules, neurofibromas, and iris hamartomas
are present in nearly all adult patients with the diagnosis of neurofi-
bromatosis type I. Vascular abnormalities have been increasingly
recognized as an uncommon complication of the disorder. Arterial
stenoses of the aorta, renal and mesenteric vessels are often long
segment and typically are not amenable to endovascular treatment.
In general, our approach is open reconstruction using aorto-
plasty or bypass, with or without reconstruction of the renal and
mesenteric arteries. Isolated renal or mesenteric stenosis may be
treated with angioplasty as a bridge to open reconstruction, but
one should expect high recurrence rates based on our recent review
of the literature.1 The dysplastic nature of the vasculopathy may
predispose patients to neointimal hyperplasia.
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Regarding “Patterns of in-stent restenosis after
carotid artery stenting: Classification and implications
for long term outcome”
With great interest we read the article by Lal et al,1 who found
that type of in-stent restenosis (ISR) and diabetes to be an indepen-
dent predictors of revascularization after carotid angioplasty and
stenting (CAS). Furthermore, the type of stent used for CAS was also
observed to influence the ISR pattern. ISR occurred more often in
patients treated with the Acculink stent (Abbott Vascular, Abbott
Park, Ill) compared with the Wallstent (Boston Scientific Corp,
Natick, Mass). However, neither in the Methods nor in Table II it is
clear how many stents of each type were used. It is therefore not
objectified if the observed phenomenon was an absolute or a relative
difference. We would like to make two remarks.
First, the incidence of ISR is highly dependent on the reste-
nosis definition and the duplex velocity criteria used. Assessment of
generally accepted duplex criteria for grading stenosis after carotid
endarterectomy has been shown to be not reliable after stenting.2,3
Although several stent types have been used in these studies,
surprisingly, a comparison for differences in duplex measurements
between stent types has not been performed.
In an animal experimental study (unpublished data), we eval-
uated velocity changes due to placement of two different carotid
stent types, the Wallstent vs Precise (Cordis, Miami Lakes, Fla).
Duplex velocities before and after stenting were measured at five
predetermined points. The Precise stent did not cause significant
higher velocities compared with baseline. However, the Wallstent
was responsible for significantly higher velocities, both in-stent and
directly after stenting, compared with the native artery.
We concluded that (1) placement of a stent in the carotid artery
can cause an increase in duplex velocities in the absence of residual or
true in-stent stenosis, (2) alterations are stent-type dependent and do
not justify a general approach to new velocity criteria indiscriminately
applied to all stents, and (3) vascular laboratories have to develop
Fig 1. This postoperativemagnetic resonance angiography shows
a functioning aorta–bilateral renal artery bypass and left common
iliac artery bypass graft.
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